Gideon Blumenthal was named vice president for Global Oncology Regulatory Affairs at Merck.
He is a former deputy director of the FDA Oncology Center of Excellence.
In the absence of the federal funding, cancer research will be leaning on private funders. But few private funders have the freedom to ask fundamental questions—questions whose answers may not have an immediate clinical impact but can dramatically advance scientific knowledge.
